Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bristol Increases Legal Reserves For Wholesaler Inventory Liability By $300 Mil.

This article was originally published in The Pink Sheet Daily

Executive Summary

The company increases wholesaler-related litigation reserves for the second time in three months. Bristol also sets aside $100 mil. for product liability and other matters.

You may also be interested in...



Nefazodone Generics Stay On Market Following FDA Analysis Of Serzone Withdrawal

Bristol's voluntary withdrawal of the antidepressant was not due to safety or effectiveness reasons, FDA says. This distinction allows generic versions of Serzone to remain on the market and may help Bristol in its upcoming liability lawsuits.

Nefazodone Generics Stay On Market Following FDA Analysis Of Serzone Withdrawal

Bristol's voluntary withdrawal of the antidepressant was not due to safety or effectiveness reasons, FDA says. This distinction allows generic versions of Serzone to remain on the market and may help Bristol in its upcoming liability lawsuits.

Bristol Takes $455 Mil. Litigation Charge, Higher Than Earlier Expectations

Bristol-Myers Squibb increased its litigation reserves to $455 mil. in the second quarter, a charge that is $55 mil. higher than earlier expectations

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS059816

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel